Table 3. Standardised incidence ratio (SIR)a and 95% confidence intervals (95% CI) for bladder cancer among patients diagnosed with benign prostatic hyperplasia in Sweden, 1964-1983 by year of BPH diagnosis.
|
All BPH patients
|
BPH without surgery
|
BPH with TURP
|
BPH with TA
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | Obs | Exp | SIR | 95% CI | |
| <1975 | (n=16 492) | (n=5249) | (n=3630) | (n=7278) | |||||||||||||
| 4–6 | 51 | 44.4 | 1.15 | (0.86–1.51) | 9 | 13.3 | 0.68 | (0.31–1.28) | 18 | 9.6 | 1.87 | (1.11–2.95) | 20 | 20.5 | 0.97 | (0.59–1.50) | |
| 7–9 | 43 | 38.7 | 1.11 | (0.80–1.50) | 11 | 10.0 | 1.10 | (0.55–1.96) | 17 | 9.0 | 1.90 | (1.10–3.04) | 13 | 18.8 | 0.69 | (0.37–1.18) | |
| 10–26 | 93 | 81.2 | 1.14 | (0.92–1.40) | 20 | 19.1 | 1.05 | (0.64–1.62) | 33 | 19.0 | 1.74 | (1.19–2.44) | 35 | 40.6 | 0.86 | (0.60–1.20) | |
| 1975–1983 | (n=44 820) | (n=7253) | (n=27 848) | (n=9287) | |||||||||||||
| 4–6 | 149 | 148.3 | 1.00 | (0.85–1.18) | 16 | 22.4 | 0.71 | (0.41–1.16) | 107 | 92.4 | 1.16 | (0.95–1.40) | 22 | 32.0 | 0.69 | (0.43–1.04) | |
| 7–9 | 112 | 100.4 | 1.12 | (0.92–1.34) | 13 | 13.5 | 0.96 | (0.51–1.65) | 74 | 60.1 | 1.23 | (0.97–1.55) | 22 | 25.7 | 0.85 | (0.54–1.29) | |
| 10–26 | 58 | 52.9 | 1.10 | (0.83–1.42) | 8 | 7.6 | 1.05 | (0.45–2.08) | 33 | 25.9 | 1.27 | (0.88–1.79) | 15 | 18.5 | 0.81 | (0.45–1.34) | |
| P b | 0.70 | 0.27 | 0.49 | 0.94 | |||||||||||||
| P c | 0.67 | ||||||||||||||||
Abbreviations: BPH=benign prostatic hyperplasia; TURP=transurethral resection of the prostate; TA=transvesicular adenomectomy.
a
Adjusted for age.
b
P-value for homogeneity test between calendar time periods.
c
P-value for overall homogeneity test between two calendar time periods and three treatment methods (three subcohorts).